116-01-01

ce is being deposited with the U.S. I hereby certify that this correspon Postal Service as Express Mail, Airbill No. EH244915365US, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: 5/3/, 2001

Signature:

Docket No.: HO-P01934US1

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ENT & TRADE re Patent Application of:

David Spencer, et al.

Application No.: 09/647,418

Filed: September 29, 2000

For:

REGULATED APOPTOSIS USING

CHEMICALLY INDUCED DIMERIZATION

OF APOPTOSISFACTORS

RECEIVED

Group Art Unit: 164/ECH CENTER 1600/2900

Examiner: Not Yet Assigned Zaman _empr

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents Washington, DC 20231

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned.

Those patent(s) or publication(s) which are marked with an asterisk (*) in the attached form PTO/SB/08 are not supplied because they were previously cited by or submitted to the Office in a prior application no. PCT/US99/06799, International Filing Date of March 30, 1999, and relied upon in this application for an earlier filing date under 35 U.S.C. 120.

A concise explanation of relevance of the items listed on form PTO/SB/08 is:

[X] not given

[] given for each listed item

2

Docket No. HO-P01934US1

JUN 0 5 2001

[] in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. HO-P01934US1. A duplicate copy of this paper is enclosed.

Dated: 5-31-01

Respectfully submitted,

Melissa D. Schwaller, Ph.D. Registered Patent Agent

Registration No.: 46,089

FULBRIGHT & JAWORSKI L.L.P.

1301 McKinney, Suite 5100

Houston, Texas 77010-3095

(713) 651-7732